Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Common Equity (2020 - 2025)

RxSight (RXST) has disclosed Common Equity for 6 consecutive years, with $275.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity fell 1.98% year-over-year to $275.7 million, compared with a TTM value of $275.7 million through Dec 2025, down 1.98%, and an annual FY2025 reading of $275.7 million, down 1.98% over the prior year.
  • Common Equity was $275.7 million for Q4 2025 at RxSight, roughly flat from $276.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $281.2 million in Q4 2024 and bottomed at -$313.4 million in Q2 2021.
  • Average Common Equity over 5 years is $141.2 million, with a median of $158.8 million recorded in 2023.
  • Peak annual rise in Common Equity hit 140.8% in 2022, while the deepest fall reached 36.41% in 2022.
  • Year by year, Common Equity stood at $138.2 million in 2021, then tumbled by 34.97% to $89.9 million in 2022, then soared by 78.37% to $160.4 million in 2023, then soared by 75.38% to $281.2 million in 2024, then fell by 1.98% to $275.7 million in 2025.
  • Business Quant data shows Common Equity for RXST at $275.7 million in Q4 2025, $276.0 million in Q3 2025, and $278.0 million in Q2 2025.